/

6978.HK

IMMUNOTECH-BClosed

0.3950−0.00 −1.25%HKD

HKSE · as of Oct 14, 03:30 ET · 15m delay

Open

0.4000

Prev close

0.4000

Day range

0.39000.4000

52-week range

0.33004.30

Volume

58.20K0.33×

Mkt cap

243.91M

P/E ttm

—

Fwd P/E

—

EPS ttm

-0.3400

Div yield

0.00%

Earnings

—

From 52w high

−90.81%

Price Chart

Yahoo Finance · delayed

6978.HKOct 14, 2026O 0.4000H 0.4000L 0.3900C 0.3950−0.0050 (−1.25%)Vol 58.20K

SMA 500.3958
SMA 2001.4629

1Y change −91.22% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

6978.HK IMMUNOTECH-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.82%
1 month: −10.23%
3 months: −24.04%
6 months: −89.24%
Year to date: −86.52%
1 year: −90.37%

Valuation & ownership

Market cap: 243.91M
Enterprise value: 584.09M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -5.27
EPS (ttm): -0.3400
EPS (forward): —
Beta (5y monthly): 0.09
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 617.50M
Float: 209.51M
Short % of float: —
Short ratio (days): —
Held by insiders: 79.65%
Held by institutions: 6.39%
Avg volume (3m): 178.52K
50-day average: 0.3951
200-day average: 1.47
52-week change: −90.37%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 46.8
vs 50-day SMA: −0.20%
vs 200-day SMA: −73.00%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.94%
Realised vol (20d, ann.): 66.6%
From 52-week high: −90.81%
From 52-week low: +19.70%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About IMMUNOTECH-B

Yahoo Finance profile

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial; 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Sector: Healthcare
Industry: Biotechnology
Employees: 189
Headquarters: Beijing, China
Website: eaal.net
Officers: Mr. Zheng Tan Executive Chairman
Mr. Jian Zhang Acting CEO & Senior VP
Dr. Hu Huaizhong Chief Scientist

SEAS

Seasonality · 6978.HK

2020–2026 · monthly returns

Strongest month Feb +20.64%Weakest month Mar −9.27%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.6	5.8	-2.2	-61.2	-25.0	-30.8	-34.3	9.9	11.5	-9.2			−86.5%
2025	19.1	61.3	0.7	-8.5	-26.3	-6.3	48.4	26.4	-15.6	-29.7	-3.2	-3.3	+27.4%
2024	-16.8	-4.6	-6.0	-11.8	-5.5	23.8	-20.0	-4.2	-2.0	-32.5	10.8	6.5	−54.0%
2023	18.8	15.5	-29.1	-17.6	11.1	13.1	-10.7	15.4	-16.9	1.3	3.5	19.6	+8.0%
2022	-56.5	-8.9	-16.6	-4.8	-1.7	2.3	-7.1	-28.7	14.7	43.5	-16.4	-4.7	−72.5%
2021	3.2	39.9	4.8	3.3	3.2	7.5	-10.6	-8.0	-1.3	3.8	-6.3	10.9	+52.0%
2020								6.7	-7.9	-15.4	12.4	10.8	+3.6%

INSD

Insider Activity · 6978.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 30, 2025	Jung (Hyun Chul)Former	—	361K	—
Nov 12, 2025	Tan (Zheng)Chairman of the Board	—	1.18M	—
Nov 11, 2025	Tan (Zheng)Chairman of the Board	—	22.77M	—
Sep 9, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	4.98M	—
Aug 27, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	5.22M	—
Aug 21, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	2.86M	—
Jul 29, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	96K	—
Jul 28, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	4K	—
Jul 27, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	43K	—
Jul 22, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	78K	—
Mar 5, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	100K	—
Mar 4, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	50K	—
Mar 3, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	50K	—
Mar 2, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	47K	—
Feb 27, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	211K	—
Feb 26, 2025	Jung (Hyun Chul)Chief Strategy Officer	—	250K	—

6978.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

6978.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About IMMUNOTECH-B

Seasonality · 6978.HK

Insider Activity · 6978.HK

Congress Trades · 6978.HK

Investors Holding 6978.HK

Investors Holding 6978.HK

Congress Trades · 6978.HK

Insider Activity · 6978.HK

Seasonality · 6978.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About IMMUNOTECH-B

Earnings & Dividends

News